Twitter

Archive for January 30th, 2012


Phase II Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Condition :   Leukaemia, Lymphocytic, Chronic Interventions :   Biological: Ofatumumab;   Drug: Bendamustine Sponsor :   GlaxoSmithKline Not yet recruiting – verified January 2012

Read More...

CNDO-109-AANK for AML in First Complete Remission (CR1)

Condition :   Acute Myeloid Leukemia Intervention :   Biological: CNDO-109-AANK Cells Sponsor :   Coronado Biosciences, Inc. Not yet recruiting – verified January 2012

Read More...

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Conditions :   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS) Intervention :   Drug: CPI-613 Sponsor :   Cornerstone Pharmaceuticals, Inc. Not yet recruiting – verified January 2012

Read More...

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II Clinical Trial.

Condition :   Recurrent Glioblastoma Intervention :   Drug: PF-299804 (Dacomitinib) Sponsors :   Grupo Español de Investigación en Neurooncología;   Pfizer Not yet recruiting – verified November 2011

Read More...

Recurrence of Hepatocellular Carcinoma

Condition :   Hepatocellular Carcinoma Intervention :   Sponsor :   Ain Shams University Recruiting – verified January 2012

Read More...

Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome

Conditions :   Silver Russell Syndrome;   Prader-Willi Syndrome Interventions :   Drug: Anastrozole;   Drug: Placebo Sponsor :   Assistance Publique - Hôpitaux de Paris Not yet recruiting – verified January 2012

Read More...

Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy

Condition :   Epithelial Ovarian Cancer Interventions :   Biological: Placebo Study Agent;   Biological: Cvac Sponsor :   Prima BioMed Ltd Recruiting – verified January 2012

Read More...

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

Conditions :   Acute Graft-versus-Host Disease;   Allogeneic Stem Cell Transplant Intervention :   Procedure: Blood samples Sponsor :   Ohio State University Comprehensive Cancer Center Not yet recruiting – verified January 2012

Read More...

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Condition :   Multiple Myeloma Intervention :   Drug: NOX-A12 Sponsor :   Noxxon Pharma AG Not yet recruiting – verified January 2012

Read More...

Comparison of Diagnostic Accuracy for Predicting Histology of Colorectal Lesions

Condition :   Colorectal Neoplasms Intervention :   Sponsor :   Shanghai Jiao Tong University School of Medicine Completed – verified January 2012

Read More...